Maintenance ICS + SABA

Maintenance ICS + SABA refers to a therapeutic regimen for asthma management, specifically evaluated by the Washington University School of Medicine in adolescent patients with poor adherence to daily maintenance inhalers. This regimen consists of a daily maintenance inhaled corticosteroid (ICS), such as fluticasone propionate (Flovent), to control underlying airway inflammation, and an as-needed short-acting beta-agonist (SABA), such as albuterol, for the rapid relief of acute symptoms. In the context of clinical research (e.g., NCT04197453), this standard-of-care approach is used as a comparator to assess the efficacy of symptom-driven ICS/LABA (long-acting beta-agonist) therapy in improving asthma control and reducing hospitalizations in non-adherent populations.

Brand names

Flovent

Other names

Maintenance ICS and Symptom Driven SABAMaintenance ICS and as-needed SABAMaintenance inhaled corticosteroid and as-needed short-acting beta-agonist